59 related articles for article (PubMed ID: 38654469)
1. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F;
Lancet Infect Dis; 2024 Apr; ():. PubMed ID: 38701823
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.
Mankad VS; Leach A; Chang Y; Wählby Hamrén U; Kiazand A; Kubiak RJ; Takas T; Villafana T; Shroff M
Pathogens; 2024 Jun; 13(6):. PubMed ID: 38921800
[TBL] [Abstract][Full Text] [Related]
3. Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month.
Gantenberg JR; van Aalst R; Bhuma MR; Limone B; Diakun D; Smith DM; Nelson CB; Bengtson AM; Chaves SS; La Via WV; Rizzo C; Savitz DA; Zullo AR
J Pediatric Infect Dis Soc; 2024 Jun; 13(6):317-327. PubMed ID: 38738450
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d'Aosta Region, Italy, in the 2023-2024 Epidemic Season.
Consolati A; Farinelli M; Serravalle P; Rollandin C; Apprato L; Esposito S; Bongiorno S
Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793800
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).
Coma E; Martinez-Marcos M; Hermosilla E; Mendioroz J; Reñé A; Fina F; Perramon-Malavez A; Prats C; Cereza G; Ciruela P; Pineda V; Antón A; Ricós-Furió G; Soriano-Arandes A; Cabezas C
Arch Dis Child; 2024 Jun; ():. PubMed ID: 38857952
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
Otsuki T; Akada S; Anami A; Kosaka K; Munjal I; Baber J; Shoji Y; Aizawa M; Swanson KA; Gurtman A
Vaccine; 2024 Jun; ():. PubMed ID: 38853036
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessment.
Estrella-Porter P; Blanco-Calvo C; Lameiras-Azevedo AS; Juaneda J; Fernández-Martínez S; Gómez-Pajares F; Tempelsman R; Roig-Sena FJ; Pérez-Panades J; Botella-Rocamora P; Lluch-Rodrigo JA; Pastor-Villalba E
Vaccine; 2024 Jun; ():. PubMed ID: 38834430
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024).
Riccò M; Cascio A; Corrado S; Bottazzoli M; Marchesi F; Gili R; Giuri PG; Gori D; Manzoni P
Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932369
[TBL] [Abstract][Full Text] [Related]
9. Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care.
Alejandre C; Penela-Sánchez D; Alsina J; Agüera M; Soler A; Moussalam S; Muñoz-Almagro C; Brotons P; Cambra FJ; Forner OR; Balaguer M; Launes C; Jordan I
Eur J Pediatr; 2024 Jun; ():. PubMed ID: 38910199
[TBL] [Abstract][Full Text] [Related]
10. Nirsevimab for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.
Aust Prescr; 2024 Jun; 47(3):102-103. PubMed ID: 38962387
[No Abstract] [Full Text] [Related]
11. High Uptake of Respiratory Syncitial Virus Prevention for Neonates in a Military Treatment Facility.
Homo RL; Groberg A; Donahue M; Halverson D; Wooten A; Ponnapakkam A
J Pediatr; 2024 Jun; ():114144. PubMed ID: 38876155
[TBL] [Abstract][Full Text] [Related]
12. Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
Wilkins D; Yuan Y; Chang Y; Aksyuk AA; Núñez BS; Wählby-Hamrén U; Zhang T; Abram ME; Leach A; Villafana T; Esser MT
Nat Med; 2024 Jun; 30(6):1785. PubMed ID: 38649782
[No Abstract] [Full Text] [Related]
13. Rapid review showed that real-world results on how nirsevimab prevented respiratory syncytial virus hospitalisations were similar to randomised trials.
Kuitunen I; Renko M
Acta Paediatr; 2024 May; ():. PubMed ID: 38780142
[No Abstract] [Full Text] [Related]
14. Early impact of nirsevimab on ambulatory all-cause bronchiolitis: a prospective multicentric surveillance study in France.
Levy C; Werner A; Rybak A; Béchet S; Batard C; Hassid F; Desandes R; Frandji B; Ouldali N; Cohen R
J Pediatric Infect Dis Soc; 2024 May; ():. PubMed ID: 38779958
[TBL] [Abstract][Full Text] [Related]
15. Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children.
Fly JH; Eiland LS; Stultz JS
Ann Pharmacother; 2024 Apr; ():10600280241243357. PubMed ID: 38654469
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
17. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
[TBL] [Abstract][Full Text] [Related]
18. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
Bergeron HC; Tripp RA
Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
